Alberto Cappelletti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alberto Cappelletti has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Cosmo Godino
Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
10 shared publications Antonio Colombo
Department of Interventional Cardiology, San Raffaele University Hospital, IRCCS, Milan, Italy
8 shared publications- Matteo Montorfano
School of Medicine, Vita-Salute San Raffaele University , Milan
8 shared publications Valeria Magni
Ospedale San Raffaele, Milano, Italy
8 shared publications- Alberto Margonato
Department of Cardiology, Cardio-Thoracic-Vascular Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
7 shared publications - Alessandro Beneduce
Heart Valve Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
6 shared publications
Latest Publications
- Open Access
- 26 July 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (7) , omac071
Cardiac electrical instability in Erdheim-Chester disease: a case report
Erdheim-Chester disease (ECD) is a rare multisystemic disorder of non-Langerhans histiocytic cells with a pleomorphic clinical presentation. It affects bones, skin, central nervous system, pituitary gland, ocular tissue, kidneys and perirenal tissue and lungs. Cardiac involvement presents usually with pericardial effusion and right atrial masses, but rarely with conduction system infiltration and subsequent arrhythmic events. Following the discovery of mutations of activating signaling kinase proteins (BRAF, MEK, ALK), the therapeutic landscape has changed to a more precise targeted treatment. Currently vemurafenib is approved for patient with end-organ dysfunction and BRAF-V600E mutation and the prognosis has dramatically improved. Here we present a case of ECD with electrical instability as main clinically relevant manifestation of cardiac involvement.
- 26 July 2022
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2022 (7) , omac071
Open AccessCardiac electrical instability in Erdheim-Chester disease: a case report
Erdheim-Chester disease (ECD) is a rare multisystemic disorder of non-Langerhans histiocytic cells with a pleomorphic clinical presentation. It affects bones, skin, central nervous system, pituitary gland, ocular tissue, kidneys and perirenal tissue and lungs. Cardiac involvement presents usually with pericardial effusion and right atrial masses, but rarely with conduction system infiltration and subsequent arrhythmic events. Following the discovery of mutations of activating signaling kinase proteins (BRAF, MEK, ALK), the therapeutic landscape has changed to a more precise targeted treatment. Currently vemurafenib is approved for patient with end-organ dysfunction and BRAF-V600E mutation and the prognosis has dramatically improved. Here we present a case of ECD with electrical instability as main clinically relevant manifestation of cardiac involvement.
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (2) , e008976
Longitudinal Invasive Hemodynamic Assessment in Patients With Acute Decompensated Heart Failure–Related Cardiogenic Shock: A Single-Center Experience
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (2) , e008976
Longitudinal Invasive Hemodynamic Assessment in Patients With Acute Decompensated Heart Failure–Related Cardiogenic Shock: A Single-Center Experience
- Open Access
- 5 November 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (11) , 1153
Non-Invasive Assessment of Left Ventricle Ejection Fraction: Where Do We Stand?
The left ventricular (LV) ejection fraction (EF) is the preferred parameter applied for the non-invasive evaluation of LV systolic function in clinical practice. It has a well-recognized and extensive role in the clinical management of numerous cardiac conditions. Many imaging modalities are currently available for the non-invasive assessment of LVEF. The aim of this review is to describe their relative advantages and disadvantages, proposing a hierarchical application of the different imaging tests available for LVEF evaluation based on the level of accuracy/reproducibility clinically required.
- 5 November 2021
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (11) , 1153
Open AccessNon-Invasive Assessment of Left Ventricle Ejection Fraction: Where Do We Stand?
The left ventricular (LV) ejection fraction (EF) is the preferred parameter applied for the non-invasive evaluation of LV systolic function in clinical practice. It has a well-recognized and extensive role in the clinical management of numerous cardiac conditions. Many imaging modalities are currently available for the non-invasive assessment of LVEF. The aim of this review is to describe their relative advantages and disadvantages, proposing a hierarchical application of the different imaging tests available for LVEF evaluation based on the level of accuracy/reproducibility clinically required.
- 1 November 2021
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 14 (11) , e008527
Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice
Trials on intra-aortic balloon pump (IABP) use in cardiogenic shock related to acute myocardial infarction have shown disappointing results. The role of IABP in cardiogenic shock treatment remains unclear, and new (potentially more potent) mechanical circulatory supports with arguably larger device profile are emerging. A reappraisal of the physiological premises of intra-aortic counterpulsation may underpin the rationale to maintain IABP as a valuable therapeutic option for patients with acute decompensated heart failure and tissue hypoperfusion. Several pathophysiological features differ between myocardial infarction- and acute decompensated heart failure–related hypoperfusion, encompassing cardiogenic shock severity, filling status, systemic vascular resistances rise, and adaptation to chronic (if preexisting) left ventricular dysfunction. IABP combines a more substantial effect on left ventricular afterload with a modest increase in cardiac output and would therefore be most suitable in clinical scenarios characterized by a disproportionate increase in afterload without profound hemodynamic compromise. The acute decompensated heart failure syndrome is characterized by exquisite afterload-sensitivity of cardiac output and may be an ideal setting for counterpulsation. Several hemodynamic variables have been shown to predict response to IABP within this scenario, potentially guiding appropriate patient selection. Finally, acute decompensated heart failure with hypoperfusion may frequently represent an end stage in the heart failure history: IABP may provide sufficient hemodynamic support and prompt end-organ function recovery in view of more definitive heart replacement therapies while preserving ambulation when used with a transaxillary approach.
- 1 November 2021
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 14 (11) , e008527
Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice
Trials on intra-aortic balloon pump (IABP) use in cardiogenic shock related to acute myocardial infarction have shown disappointing results. The role of IABP in cardiogenic shock treatment remains unclear, and new (potentially more potent) mechanical circulatory supports with arguably larger device profile are emerging. A reappraisal of the physiological premises of intra-aortic counterpulsation may underpin the rationale to maintain IABP as a valuable therapeutic option for patients with acute decompensated heart failure and tissue hypoperfusion. Several pathophysiological features differ between myocardial infarction- and acute decompensated heart failure–related hypoperfusion, encompassing cardiogenic shock severity, filling status, systemic vascular resistances rise, and adaptation to chronic (if preexisting) left ventricular dysfunction. IABP combines a more substantial effect on left ventricular afterload with a modest increase in cardiac output and would therefore be most suitable in clinical scenarios characterized by a disproportionate increase in afterload without profound hemodynamic compromise. The acute decompensated heart failure syndrome is characterized by exquisite afterload-sensitivity of cardiac output and may be an ideal setting for counterpulsation. Several hemodynamic variables have been shown to predict response to IABP within this scenario, potentially guiding appropriate patient selection. Finally, acute decompensated heart failure with hypoperfusion may frequently represent an end stage in the heart failure history: IABP may provide sufficient hemodynamic support and prompt end-organ function recovery in view of more definitive heart replacement therapies while preserving ambulation when used with a transaxillary approach.
- Open Access
- 4 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 1974
The Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach
Background. Myocarditis lacks systematic characterization in COVID-19 patients. Methods. We enrolled consecutive patients with newly diagnosed myocarditis in the context of COVID-19 infection. Diagnostic and treatment strategies were driven by a dedicated multidisciplinary disease unit for myocarditis. Multimodal outcomes were assessed during prospective follow-up. Results. Seven consecutive patients (57% males, age 51 ± 9 y) with acute COVID-19 infection received a de novo diagnosis of myocarditis. Endomyocardial biopsy was of choice in hemodynamically unstable patients (n = 4, mean left ventricular ejection fraction (LVEF) 25 ± 9%), whereas cardiac magnetic resonance constituted the first exam in stable patients (n = 3, mean LVEF 48 ± 10%). Polymerase chain reaction (PCR) analysis revealed an intra-myocardial SARS-CoV-2 genome in one of the six cases undergoing biopsy: in the remaining patients, myocarditis was either due to other viruses (n = 2) or virus-negative (n = 3). Hemodynamic support was needed for four unstable patients (57%), whereas a cardiac device implant was chosen in two of four cases showing ventricular arrhythmias. Medical treatment included immunosuppression (43%) and biological therapy (29%). By the 6-month median follow-up, no patient died or experienced malignant arrhythmias. However, two cases (29%) were screened for heart transplantation. Conclusions. Myocarditis associated with acute COVID-19 infection is a spectrum of clinical manifestations and underlying etiologies. A multidisciplinary approach is the cornerstone for tailored management.
- 4 May 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 1974
Open AccessThe Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary Approach
Background. Myocarditis lacks systematic characterization in COVID-19 patients. Methods. We enrolled consecutive patients with newly diagnosed myocarditis in the context of COVID-19 infection. Diagnostic and treatment strategies were driven by a dedicated multidisciplinary disease unit for myocarditis. Multimodal outcomes were assessed during prospective follow-up. Results. Seven consecutive patients (57% males, age 51 ± 9 y) with acute COVID-19 infection received a de novo diagnosis of myocarditis. Endomyocardial biopsy was of choice in hemodynamically unstable patients (n = 4, mean left ventricular ejection fraction (LVEF) 25 ± 9%), whereas cardiac magnetic resonance constituted the first exam in stable patients (n = 3, mean LVEF 48 ± 10%). Polymerase chain reaction (PCR) analysis revealed an intra-myocardial SARS-CoV-2 genome in one of the six cases undergoing biopsy: in the remaining patients, myocarditis was either due to other viruses (n = 2) or virus-negative (n = 3). Hemodynamic support was needed for four unstable patients (57%), whereas a cardiac device implant was chosen in two of four cases showing ventricular arrhythmias. Medical treatment included immunosuppression (43%) and biological therapy (29%). By the 6-month median follow-up, no patient died or experienced malignant arrhythmias. However, two cases (29%) were screened for heart transplantation. Conclusions. Myocarditis associated with acute COVID-19 infection is a spectrum of clinical manifestations and underlying etiologies. A multidisciplinary approach is the cornerstone for tailored management.
- 1 September 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 290, 52-58
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry)
- 1 September 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 290, 52-58
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry)
- 29 April 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 94 (7) , 972-979
One‐year clinical outcome of biodegradable polymer sirolimus‐eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry
Background The ULISSE registry has demonstrated the real‐world performance of the Ultimaster biodegradable polymer sirolimus‐eluting stent (BP‐SES) in a large cohort of patients undergoing percutaneous coronary intervention, including a large proportion of patients presenting with acute myocardial infarction (AMI). Methods We performed a subgroup analysis of the ULISSE registry in AMI patients and compared the outcomes of this vulnerable cohort with that of patients presenting without AMI (non‐AMI). The primary end point was the incidence of 1‐year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV‐MI), and clinically indicated target lesion revascularization (TLR). Results Of 1,660 patients included in the ULISSE registry, 381(23%) presented with AMI, 207(54.3%) non‐ST elevation myocardial infarction, and 174(45.7%) ST‐elevation myocardial infarction. Compared with non‐AMI patients, those with AMI were more frequently female and smokers, with lower left ventricular ejection fraction (LVEF) and chronic kidney disease requiring dialysis. At 1 year, TLF rate was significantly higher in AMI than non‐AMI patients (7.9 vs. 4.1%; HR 1.98, CI 95% 1.22–3.23; p = .005) driven by higher rate of cardiac death (4.0 vs. 1.1%; HR 3.59, CI 95% 1.64–7.88; p = .01) and TV‐MI (2.8 vs 0.9%; HR 2.99,CI 95% 1.22–7.37; p = .01), without differences in TLR rate (4.3 vs. 2.9%,HR 0.66, CI95% 0.35–1.25; p = .2). At multivariate Cox regression analysis, eGFR <40 mL/min (HR: 2.868) and LVEF <40% (HR: 2.394) were the only independent predictors of TLF. Conclusions In AMI patients, Ultimaster BP‐SES implantation was associated with higher rate of TLF and definite stent thrombosis compared with non‐AMI patients. The high incidence of adverse events was mainly driven by the unfavorable baseline risk profile.
- 29 April 2019
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 94 (7) , 972-979
One‐year clinical outcome of biodegradable polymer sirolimus‐eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry
Background The ULISSE registry has demonstrated the real‐world performance of the Ultimaster biodegradable polymer sirolimus‐eluting stent (BP‐SES) in a large cohort of patients undergoing percutaneous coronary intervention, including a large proportion of patients presenting with acute myocardial infarction (AMI). Methods We performed a subgroup analysis of the ULISSE registry in AMI patients and compared the outcomes of this vulnerable cohort with that of patients presenting without AMI (non‐AMI). The primary end point was the incidence of 1‐year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV‐MI), and clinically indicated target lesion revascularization (TLR). Results Of 1,660 patients included in the ULISSE registry, 381(23%) presented with AMI, 207(54.3%) non‐ST elevation myocardial infarction, and 174(45.7%) ST‐elevation myocardial infarction. Compared with non‐AMI patients, those with AMI were more frequently female and smokers, with lower left ventricular ejection fraction (LVEF) and chronic kidney disease requiring dialysis. At 1 year, TLF rate was significantly higher in AMI than non‐AMI patients (7.9 vs. 4.1%; HR 1.98, CI 95% 1.22–3.23; p = .005) driven by higher rate of cardiac death (4.0 vs. 1.1%; HR 3.59, CI 95% 1.64–7.88; p = .01) and TV‐MI (2.8 vs 0.9%; HR 2.99,CI 95% 1.22–7.37; p = .01), without differences in TLR rate (4.3 vs. 2.9%,HR 0.66, CI95% 0.35–1.25; p = .2). At multivariate Cox regression analysis, eGFR <40 mL/min (HR: 2.868) and LVEF <40% (HR: 2.394) were the only independent predictors of TLF. Conclusions In AMI patients, Ultimaster BP‐SES implantation was associated with higher rate of TLF and definite stent thrombosis compared with non‐AMI patients. The high incidence of adverse events was mainly driven by the unfavorable baseline risk profile.